Disease-Modifying Therapies
PreclinicalSmall molecule
BiogenDisease-Modifying Therapies is one of 60 small molecule programs targeting Relapsing-Remitting Multiple Sclerosis. It is currently in Preclinical.
2
Indications
3
Total Trials
2
Active Trials
59
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
560 competitors in Multiple Sclerosis
#DrugCompanyPhaseTrials
1Betaseron
BayerPreclinical
Kesimpta
NovartisPreclinical
Tysabri
BiogenPreclinical
Avonex
EMD SeronoPreclinical
Campath
GGenzyme, a Sanofi Company
Preclinical
Flomax
SanofiPreclinical
Novantrone
PfizerPreclinical
Pred Forte
NovartisPreclinical
Myfortic
NovartisPreclinical
Circadin
NNeurim Pharmaceuticals Ltd.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Multiple Sclerosis2 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Disease-Modifying Therapies. EMBL-EBI & Wellcome Sanger Institute.
- [4]